Eli Lilly and Co (BSP:LILY34) Stock News, Headlines & Updates
Eli Lilly and Co Stock News from GuruFocus
- 1
- 2
- 3
- 4
Jul 23, 2025
Eli Lilly (LLY) Collaborates on Alzheimer's Diagnostic Test with CE Mark Approval | LLY Stock News
GuruFocus News • 5:45am
Jul 17, 2025
Eli Lilly and Co (LLY) Shares Gap Down to $765.51 on Jul 17
GuruFocus News • 12:04pm
Jul 15, 2025
Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment
GuruFocus News • 7:58am
Jul 11, 2025
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
Nauman khan • 9:22am
Eli Lilly (LLY) Price Target Raised by Guggenheim | LLY Stock News
GuruFocus News • 8:02am
Jul 10, 2025
Eli Lilly (LLY) Receives Price Target Upgrade by Morgan Stanley | LLY Stock News
GuruFocus News • 11:33am
Eli Lilly (LLY) Price Target Boosted by Morgan Stanley | LLY Stock News
GuruFocus News • 8:04am
Jul 09, 2025
Big Pharma on the Clock as 200% Tariffs Loom
Undercovered Deep Insights • 12:13pm
Eli Lilly (LLY) Gains FDA Approval for Updated Alzheimer's Treatment Dosing
GuruFocus News • 6:56am
Eli Lilly (LLY) Gains FDA Approval for Kisunla's New Dosing Schedule in Alzheimer's Treatment | LLY Stock News
GuruFocus News • 6:18am
Eli Lilly's Kisunla Receives FDA Approval for Updated Dosing in Alzheimer's Treatment | LLY stock news
GuruFocus News • 6:03am
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease | LLY Stock News
GuruFocus News • 6:00am
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
PRNewswire • 6:00am
Jun 30, 2025
Eli Lilly (LLY) Faces Rising Competition from Innovent Biologics
GuruFocus News • 8:58am
Jun 26, 2025
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1.3 Billion Deal | LLY Stock News
GuruFocus News • 4:45pm
Eli Lilly (LLY) Expands Mounjaro in India, Competing with Novo Nordisk
GuruFocus News • 5:55am
Jun 25, 2025
Eli Lilly (LLY): Rising Adherence to GLP-1 Treatments in 2024
GuruFocus News • 9:58am
Eli Lilly (LLY) Poised for Growth in Emerging Obesity Market | LLY Stock News
GuruFocus News • 5:49am
Jun 24, 2025
Eli Lilly's (LLY) Olomorasib Gains Orphan Drug Status for Lung Cancer Treatment
GuruFocus News • 5:55pm
Eli Lilly (LLY) Gains FDA Orphan Status for KRAS G12C-Mutant NSCLC Drug | LLY Stock News
GuruFocus News • 2:15pm
California Cuts Medicaid Coverage for Eli Lilly's (LLY) Weight Loss Drug | LLY Stock News
GuruFocus News • 8:45am
Jun 23, 2025
Eli Lilly and Co (LLY) Announces Third Quarter 2025 Dividend | LLY stock news
GuruFocus News • 12:02pm
Eli Lilly (LLY) Maintains Quarterly Dividend at $1.50
GuruFocus News • 11:55am
Eli Lilly (LLY) Shows Promising Results in Diabetes Treatment Trials | LLY Stock News
GuruFocus News • 11:24am
Eli Lilly (LLY) Announces Promising Phase 3 Trial Results for Diabetes Drug | LLY Stock News
GuruFocus News • 11:19am
Eli Lilly's (LLY) Zepbound Faces New Competition from Ecnoglutide | LLY Stock News
GuruFocus News • 11:19am
Lilly declares third-quarter 2025 dividend
PRNewswire • 11:00am
Eli Lilly's (LLY) Bimagrumab Shows Promising Weight Loss Results
GuruFocus News • 10:57am
Eli Lilly's (LLY) Insulin Efsitora Shows Promise in Phase 3 Trials
GuruFocus News • 10:55am
Lilly declares third-quarter 2025 dividend | LLY Stock News
GuruFocus News • 10:45am
Jun 22, 2025
Eli Lilly's Efsitora Alfa Shows Promising Results in Phase 3 Trials | LLY stock news
GuruFocus News • 2:01pm
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
PRNewswire • 2:00pm
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials | LLY Stock News
GuruFocus News • 1:45pm
Eli Lilly (LLY) to Acquire Verve Therapeutics in $1.3B Deal
GuruFocus News • 8:55am
Jun 21, 2025
Eli Lilly (LLY) Achieves Key Results in Phase 3 Diabetes Trial
GuruFocus News • 9:55am
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medici
GuruFocus News • 8:15am
Jun 20, 2025
Eli Lilly (LLY) to Reveal Key Phase 3 Trial Results for Orforglipron
GuruFocus News • 2:55pm
Eli Lilly (LLY) Gains Boost from New Obesity Drug Recommendations
GuruFocus News • 12:55pm
Eli Lilly (LLY) Maintains Buy Rating and Price Target at $936 | LLY Stock News
GuruFocus News • 9:30am
Eli Lilly (LLY) to Appeal UK Rejection of Alzheimer's Drug Kisunla
GuruFocus News • 6:57am
- 1
- 2
- 3
- 4
Show
Entries
Headlines
Total 0- 1
No recent news